TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Polynovo ( (AU:PNV) ) has shared an announcement.
PolyNovo’s 2025 Annual Report highlights its strategic focus on expanding global reach and product offerings, particularly with NovoSorb MTX. The company is enhancing its market position by scaling operations and driving growth through innovation, which is expected to benefit stakeholders by improving patient outcomes and increasing market penetration.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo, headquartered in Melbourne, Australia, is a medical technology company specializing in the management of acute and complex wounds. The company offers innovative product solutions such as NovoSorb BTM and NovoSorb MTX, which enhance patient outcomes across a wide range of wounds. PolyNovo has treated over 84,000 patients in 46 countries and is expanding its global presence through new products and clinical indications.
YTD Price Performance: -25.25%
Average Trading Volume: 2,666,783
Technical Sentiment Signal: Hold
Current Market Cap: A$1.05B
Find detailed analytics on PNV stock on TipRanks’ Stock Analysis page.